DBV Technologies Announces 3-Year Results From EPITOPE Phase 3 Open-Label Extension Study; Data Provided Support That Continued Treatment With VIASKIN Peanut Showed Improveemntn Through 36 Months Of Treatment Across All Efficacy Parameters

DBV Technologies宣布EPITOPE第三阶段开放标签扩展研究的三年结果；数据提供了支持，显示持续使用VIASKIN花生治疗的患者在各项疗效参数上经过36个月的治疗后有明显改善。

Benzinga · 01/08 16:08

EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN Peanut patch in toddlers 1 – 3 years through 36 months
68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12
No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE
DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FDA
DBV to highlight these data in multiple abstract presentations at the Eastern Food Allergy & Comorbidity Conference, January 9-12, in Palm Beach, Florida
- Company to host investor webcast today at 5:00pm ET

EPITOPE OLE数据显示，VIASKIN花生贴片对1至3岁幼儿的治疗效益在36个月内持续改善。
68.2%的受试者在口服食物挑战中完成（约12-14颗花生）而未达到停止标准，12个月时为30.7%
在EPITOPE OLE的第三年中，没有发生与治疗相关的过敏反应或严重的治疗相关不良事件（TEAE）
DBV还公布了EPITOPE每日贴片佩戴时间的数据，支持公司与FDA分享的提议标签方案。
DBV将在2025年1月9日至12日在佛罗里达州棕榈滩举行的东部食品过敏与共病会议上，通过多个摘要展示这些数据。
- 公司将在今日东部时间下午5:00举办投资者网络研讨会

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

风险及免责提示